The power of autoantibodies as biomarkers of the immune response to cancer

Immunotherapy has revolutionised the treatment of cancers, improving the prognosis for a variety of malignancies. One of the key elements in the immunotherapy war chest are checkpoint inhibitors (CPIs) which have been the main drivers behind this progress. These pioneering drugs, however, are not perfect, with a significant proportion of patients not responding. They also have the potential to cause serious and even life-threatening adverse events. Autoantibody profiling can further drive the potential of CPI therapy; providing insights into the patients most likely to respond to therapy and enabling proactive management of adverse events.

This white paper examines the power of autoantibody profiling in unlocking the full potential of immunotherapy. Oncimmune’s ImmunoINSIGHTS can leverage the power of these antibodies – regarded as sentinels of the adaptive immune response to cancer – as prospective biomarkers in immunotherapy development programmes. Our work has demonstrated the ability of autoantibodies to help predict therapy outcomes, immune-related adverse events (irAEs) and immune activation following combination therapies.